Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Genelux (GNLX) EBT (2022 - 2025)

Genelux has reported EBT over the past 4 years, most recently at -$9.3 million for Q4 2025.

  • Quarterly results put EBT at -$9.3 million for Q4 2025, up 2.75% from a year ago — trailing twelve months through Dec 2025 was -$34.4 million (down 11.58% YoY), and the annual figure for FY2025 was -$32.5 million, down 4.86%.
  • EBT for Q4 2025 was -$9.3 million at Genelux, down from -$8.0 million in the prior quarter.
  • Over the last five years, EBT for GNLX hit a ceiling of $6.0 million in Q3 2022 and a floor of -$9.6 million in Q1 2023.
  • Median EBT over the past 4 years was -$6.8 million (2023), compared with a mean of -$6.2 million.
  • Biggest five-year swings in EBT: plummeted 188.95% in 2023 and later grew 17.99% in 2024.
  • Genelux's EBT stood at -$3.5 million in 2022, then tumbled by 93.62% to -$6.8 million in 2023, then tumbled by 41.08% to -$9.5 million in 2024, then rose by 2.75% to -$9.3 million in 2025.
  • The last three reported values for EBT were -$9.3 million (Q4 2025), -$8.0 million (Q3 2025), and -$7.6 million (Q2 2025) per Business Quant data.